Prof. Laurence Bordenave
Prof. Laurence Bordenave is professor in biophysics and nuclear medicine and head of the department of nuclear medicine at Bordeaux University hospital. Her research mainly focuses on translational applied research in arterial replacement and bioartificial vascular substitutes in vitro and in vivo, and on proof of concept, technological transfer as well as preclinical and clinical validations
Summary CV
Laurence Bordenave, MD PhD, born in 1955, is professor in biophysics and nuclear medicine at Bordeaux University and head of the department of nuclear medicine at Bordeaux University hospital. She is also medical coordinator of the Center for Clinical Investigation – section on technological innovation (CIC-IT), responsible for biomaterials and implantable medical devices (1401 – BioDIM), quality medical referent of the Medical Devices Program (PIM) and a member of Inserm Unit UMR1026 on tissue bio-engineering (BioTis). She is involved in vectorised internal radiation therapy, clinical research programs (PHRC) and industrial protocols. She also holds the authorization to hold and use radioelements in unsealed sources. Pr. Bordenave is involved in various teaching activities and responsibilities. Her research mainly focuses on translational applied research in arterial replacement and bioartificial vascular substitutes in vitro and in vivo (BioTis), and on proof of concept, technological transfer, as well as preclinical and clinical validations (CIC-TI BioDiMI). She was elected as a member of the CSS7 commission at INSERM from 2008 to 2012, and was also elected at the research and teaching council of Bordeaux University, for the Life and Health Sciences Research department, and was nominated at the office for Clinical Research and Innovation at Bordeaux University Hospital (DRCI).
Selected References
1. Ploux S., Riviere A., Amraoui S., Whinnett Z., Barandon L., Lafitte S., Ritter P., Papaioannou G., Clementy J., Jais P., Bordenave L., Haissaguerre M., Bordachar P. Positron emission tomography in patients with suspected pacing system infections may play a critical role in difficult cases. Heart Rhythm, 2011, 8: 1478-81.
2. M. Rémy, M. Durand, P. Menu, Jc. Voegel, Jf. Ponsot, X. Berard, Mf. Harmand, L. Bordenave. Interspecies differences with in vitro and in vivo models of vascular tissue engineering. Biomaterials, 2013, 34:9842-9852
3. L. Rami., Auguste P. Thebaud N.B., Bareille R., Daculsi R., Ripoche J., L. Bordenave. IQ Domain GTPase-Activating Protein 1 is involved in Shear Stress-Induced Progenitor-Derived Endothelial Cell Alignment. PLoS One, 2013 Nov 22; 8:e79919.
4. Tlili G., Picard F., Pinaquy J.B., Domingues.Dos.Santos P., Bordenave L. The usefulness of FDG PET/CT imaging in suspicion of LVAD infection. J. Nucl. Cardiol. 2014, Aug; 21:845-848.
5. Berard X., Pinaquy J.B, Stecken L., Wille H., Deglise S., Ducasse E., Midy D., Bordenave L. Utility of 18F.FDG PET.CT and sonication for detection of infection following peripheral stent fracture. Circulation, 2014 Aug, 129: 2437-2439
>140 articles (HIndexWOS: 30).